尿激酶型纤溶酶原激活因子在上皮性卵巢癌中的表达及其与临床预后的关系

Expression of urokinase-type plasminogen activator in epithelial ovarian cancer and its relationship with clinical prognosis

目的探讨尿激酶型纤溶酶原激活因子(urokinase-type plasminogen activator,uPA)在不同类型的上皮性卵巢肿瘤中的表达及其与临床预后的关系。方法应用SP法,对85例上皮性卵巢癌、16例上皮性卵巢交界性肿瘤、39例上皮性卵巢良性肿瘤、24例正常卵巢组织的手术标本进行uPA表达的检测,并对uPA的表达与肿瘤分化程度、临床分期、有无淋巴转移、有无大网膜转移以及生存期的关系进行统计分析。结果 uPA在上皮性卵巢癌中的阳性表达率为75.3%,明显高于上皮性卵巢交界性肿瘤(43.8%)、上皮性卵巢良性肿瘤(35.9%)及卵巢正常组织(12.5%)。高、中分化的上皮性卵巢癌中uPA的表达率为45.5%,明显低于低分化的上皮性卵巢癌(84.6%)。uPA在Ⅲ-Ⅳ期的上皮性卵巢癌的表达率(85.5%)高于Ⅰ-Ⅱ期的上皮性卵巢癌(26.7%)。有淋巴转移、有大网膜转移、生存期<5年的上皮性卵巢癌中uPA的阳性表达率分别高于无淋巴转移、无大网膜转移、生存期≥5年的上皮性卵巢癌中uPA的阳性表达率,其间存在统计学差异(P<0.05)。结论 uPA的高表达与上皮性卵巢癌的发生、发展、侵袭、转移以及预后密切相关。

Objective To investigate the expression of urokinase-type plasminogen activator（uPA） in different types of epithelial ovarian tumor and its relationship with the clinical prognosis. Methods SP immunohistochemical staining was used to determine the expression of uPA in 85 cases of ovarian cancer,16 cases of borderline ovarian tumor,39 cases of benign ovarian tumor and 24 cases of normal ovarian tissue.The relationship between the expression of uPA and its differentiation,clinical stage,lymph node metastasis,omental metastasis and survival time were analyzed. Results In 85 cases of epithelial ovarian cancer,the positive expression rate of uPA was 75.3%,significantly higher than those in borderline ovarian tumor（43.8%） ,benign ovarian tumor（35.9%） and normal ovarian tissue（12.5%）（P0.05） .The positive expression rate of uPA in patients with lymph node metastasis,omentum metastasis and the survival time 5 years was significantly higher than that in patients with no lymph node metastasis,with no omentum metastasis and the survival time ≥5 years,respectively（P0.05） . Conclusion The high expression of uPA is related to the occurrence,development,invasion,metastasis and prognosis in epithelial ovarian tumor.